What are the health benefits of psilocybin?

2023 © Wikiask
Main topic: Science
Short answer:

There's no definite answer as research is ongoing. In 2019, the US Food and Drug Administration (FDA) designated psilocybin a breakthrough therapy for major depressive disorder and treatment-resistant depression. This designation expedites the assessment of promising drug therapies for potential approval.

Psilocybin is currently studied for a wide range of mental illnesses[edit]

Areas of research include[1][2]:

  • Anxiety disorders,
  • Treatment-resistant depression and major depressive disorder (MDD),[3]
  • Chronic suicidal ideation,[4]
  • Anxiety and depression in patients with a terminal illness such as life-threatening cancer,[5][6][7]
  • Anxiety and depression in patients with Alzheimer's[8] or Parkinson's disease,[9]
  • Addictions such as alcohol, tobacco,[10] cocaine,[11] methamphetamine,[12] and gambling,[13]
  • Binge eating disorder (BED),[14]
  • Lyme disease,[15]
  • Anorexia nervosa,[16]
  • Migraine headache,[17] chronic cluster headache,[18] and concussion headache,[19]
  • Chronic pain,[20][21]
  • Fibromyalgia,[22]
  • Obsessive compulsive disorder (OCD),[23]
  • Drug dependence,
  • Post-traumatic stress disorder (PTSD),[24]
  • Mood disorders.[25]

Psilocybin hasn't been approved yet as a treatment for any disease[edit]

Research is still ongoing and larger studies are needed to show the effectiveness and safety of psilocybin. In 2019, the US Food and Drug Administration (FDA) designated psilocybin a breakthrough therapy for major depressive disorder and treatment-resistant depression. This designation expedites the assessment of promising drug therapies for potential approval. As of 2022, psilocybin therapy is not legally available outside clinical trials.[26][27]

References[edit]

  1. ↑ Psychedelic therapy: a roadmap for wider acceptance and utilization
  2. ↑ FDA Grants Psilocybin Second Breakthrough Therapy Designation for Resistant Depression
  3. ↑ Bender, David; Hellerstein, David J. (2022-06-01). "Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research". Psychopharmacology. 239 (6): 1907–1932. doi:10.1007/s00213-021-06049-6. ISSN 1432-2072.
  4. ↑ M.D, Scott T. Aaronson (2022-02-04). "The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation". Sheppard Pratt Health System, COMPASS Pathways. Cite journal requires |journal= (help)
  5. ↑ Schimmel, Nina; Breeksema, Joost J; Smith-Apeldoorn, Sanne Y; Veraart, Jolien; van den Brink, Wim; Schoevers, Robert A (2022). "Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review". Psychopharmacology. 239: 15–33. doi:10.1007/s00213-021-06027-y. ISSN 0033-3158.
  6. ↑ Ross, Stephen; Bossis, Anthony; Guss, Jeffrey; Agin-Liebes, Gabrielle; Malone, Tara; Cohen, Barry; Mennenga, Sarah E; Belser, Alexander; Kalliontzi, Krystallia; Babb, James; Su, Zhe (2016). "Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial". Journal of Psychopharmacology (Oxford, England). 30 (12): 1165–1180. doi:10.1177/0269881116675512. ISSN 0269-8811. PMC 5367551. PMID 27909164.
  7. ↑ "CTG Labs - NCBI". beta.clinicaltrials.gov. Retrieved 2022-09-30.
  8. ↑ Johns Hopkins University (2022-03-09). "Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease". Cite journal requires |journal= (help)
  9. ↑ MD/PhD, Joshua Woolley (2021-09-01). "Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study". Joshua Woolley, MD/PhD. Cite journal requires |journal= (help)
  10. ↑ dos Santos, Rafael G.; Osório, Flávia L.; Crippa, José Alexandre S.; Riba, Jordi; Zuardi, Antônio W.; Hallak, Jaime E. C. (2016). "Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years". Therapeutic Advances in Psychopharmacology. 6 (3): 193–213. doi:10.1177/2045125316638008. ISSN 2045-1253. PMC 4910400. PMID 27354908.
  11. ↑ Hendricks, Peter (2022-08-01). "Psilocybin-facilitated Treatment for Cocaine Use: A Pilot Study". University of Alabama at Birmingham. Cite journal requires |journal= (help)
  12. ↑ Portland VA Research Foundation, Inc (2022-07-12). "Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder". Steven & Alexandra Cohen Foundation. Cite journal requires |journal= (help)
  13. ↑ "Gambling Addiction Study". Imperial College London. Retrieved 2022-09-30.
  14. ↑ TRYP Therapeutics (2022-04-27). "A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder". Cite journal requires |journal= (help)
  15. ↑ Johns Hopkins University (2022-08-02). "Effects of Psilocybin in Post-Treatment Lyme Disease". Steven and Alexandra Cohen Foundation. Cite journal requires |journal= (help)
  16. ↑ "Panorexia". Imperial College London. Retrieved 2022-09-30.
  17. ↑ Yale University (2022-09-02). "Repeat Dosing of Psilocybin in Headache Disorders". Wallace Research Foundation. Cite journal requires |journal= (help)
  18. ↑ Knudsen, Gitte Moos (2022-08-08). "Prophylactic Effects of Psilocybin on Chronic Cluster Headache: an Open-label Clinical Trial and Neuroimaging Study". Gitte Moos Knudsen. Cite journal requires |journal= (help)
  19. ↑ Yale University (2022-07-27). "Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II". Cite journal requires |journal= (help)
  20. ↑ Hendricks, Peter (2022-08-24). "Psilocybin-facilitated Treatment for Chronic Pain". University of Alabama at Birmingham. Cite journal requires |journal= (help)
  21. ↑ MD/PhD, Joshua Woolley (2022-04-27). "A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain". Joshua Woolley, MD/PhD. Cite journal requires |journal= (help)
  22. ↑ "PsiloPain". Imperial College London. Retrieved 2022-09-30.
  23. ↑ "PsilOCD". Imperial College London. Retrieved 2022-09-30.
  24. ↑ Davis, Alan K. (2022-09-21). "Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial". Ohio State University. Cite journal requires |journal= (help)
  25. ↑ Vollenweider, Franz X.; Kometer, Michael (2010). "The neurobiology of psychedelic drugs: implications for the treatment of mood disorders". Nature Reviews. Neuroscience. 11 (9): 642–651. doi:10.1038/nrn2884. ISSN 1471-0048. PMID 20717121.
  26. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named nature
  27. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named FDA
Retrieved from "https://wikiask.org/w/index.php?title=What_are_the_health_benefits_of_psilocybin%3F&oldid=6908"